Venetoclax – The game-changer in hematology
- 1 January 2020
- journal article
- review article
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 41 (4), 555-558
- https://doi.org/10.4103/ijmpo.ijmpo_260_20
Abstract
The introduction of small molecule inhibitors in many hematological malignancies made a landmark achievement in this field with a dramatic change in the survival outcome. Venetoclax is a B-cell lymphoma-2 inhibitor which has become the game-changer molecule in chronic lymphocytic leukemia and acute myeloid leukemia. This review is intended to summarize the mechanism of action, side effects, dosage, and different phases of clinical trials of this drug with review of literature.Keywords
This publication has 15 references indexed in Scilit:
- Ibrutinib and Venetoclax for First-Line Treatment of CLLThe New England Journal of Medicine, 2019
- Agressive LymphomasPublished by Springer Science and Business Media LLC ,2019
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018
- Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapyHaematologica, 2018
- Venetoclax: Targeting BCL2 in Hematological CancersPublished by Springer Science and Business Media LLC ,2018
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2018
- Small Molecules in HematologyPublished by Springer Science and Business Media LLC ,2018
- The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismBlood, 2016
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2016
- Clearance of systemic hematologic tumors by venetoclax (Abt‐199) and navitoclaxPharmacology Research & Perspectives, 2015